论文部分内容阅读
1992年7月至1995年10月作者对35例中晚期肝癌(其中Ⅱ期16例、Ⅲ期19例)病人应用肝动脉化疗栓塞及生物反应调节剂联合治疗,并进行疗效观察。其结果:CR+PR 23例,占65.7％;SR 9例,占25.7％;PD 3例,占8.6％,为12例病人提供了外科手术机会,病人1年、1年半、2年的生存率分别为57.1％、40％、17.1％,且治疗后毒副反应轻、少。这表明,在介入治疗中联合应用生物反应调节剂,有利于提高中晚期肝癌的疗效。
From July 1992 to October 1995, the authors applied hepatic arterial chemoembolization and biological response modifiers to 35 patients with advanced hepatocellular carcinoma (16 in stage II and 19 in stage III) and observed the effect. The results: 23 cases of CR+PR, accounting for 65.7%; 9 cases of SR, accounting for 25.7%; 3 cases of PD, accounting for 8.6%, provided surgical intervention for 12 cases, 1 year, 1 year and a half, and 2 years for patients. The survival rates were 57.1%, 40%, and 17.1%, respectively, and the toxicity after the treatment was mild or less. This shows that the combined use of biological response modifiers in interventional treatment will help improve the efficacy of advanced liver cancer.